Page last updated: 2024-10-28

idebenone and Diabetes Mellitus, Type 2

idebenone has been researched along with Diabetes Mellitus, Type 2 in 2 studies

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Hui, C1
Tomilov, A1
Garcia, C1
Jiang, X1
Fash, DM1
Khdour, OM1
Rosso, C1
Filippini, G1
Prato, M1
Graham, J1
Hecht, S1
Havel, P1
Cortopassi, G1
Dassano, A1
Loretelli, C1
Fiorina, P1

Other Studies

2 other studies available for idebenone and Diabetes Mellitus, Type 2

ArticleYear
Novel idebenone analogs block Shc's access to insulin receptor to improve insulin sensitivity.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 132

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin; Insulin Resistance; Mi

2020
Idebenone and T2D: A new insulin-sensitizing drug for personalized therapy.
    Pharmacological research, 2019, Volume: 139

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Precision Medicine; Src

2019